UBXN11 and chronic kidney disease: The tolvaptan and SOC groups each had a mean age of 60.2 years (range of 56.0-65.0 for tolvaptan and 55.1-67.0 for SOC), 53.7% were female, 69.5% were in CKD G3, and 30.5% were in CKD G4.